Teva Pharmaceutical Industries’ (TEVA) “Hold” Rating Reiterated at Maxim Group

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reissued by Maxim Group in a report issued on Monday.

A number of other equities analysts also recently commented on the company. Goldman Sachs Group raised their price objective on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, January 11th. Credit Suisse Group restated an “underperform” rating and issued a $8.00 price objective (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 price objective on the stock in a report on Friday, December 15th. Royal Bank of Canada set a $11.00 price objective on Teva Pharmaceutical Industries and gave the stock a “sell” rating in a report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday, December 14th. Eight investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus price target of $21.32.

Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.32 during trading on Monday, hitting $21.02. The stock had a trading volume of 20,721,080 shares, compared to its average volume of 23,654,961. The stock has a market cap of $20,960.00, a P/E ratio of -3.58, a price-to-earnings-growth ratio of 1.48 and a beta of 0.54. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.08). Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. analysts expect that Teva Pharmaceutical Industries will post 3.74 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $106,000. Penserra Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $129,000. Fieldpoint Private Securities LLC purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Chevy Chase Trust Holdings Inc. increased its holdings in Teva Pharmaceutical Industries by 81.5% during the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock worth $215,000 after purchasing an additional 5,497 shares during the last quarter. Finally, Bank of Nova Scotia increased its holdings in Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares during the last quarter. Institutional investors own 51.89% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/22/teva-pharmaceutical-industries-teva-hold-rating-reiterated-at-maxim-group.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply